Related Experiment Video
Updated: Jul 18, 2026
Murine Cervical Heart Transplantation Model Using a Modified Cuff Technique
Published on: October 12, 2014
Cytoprotective gene HO-1 and chronic rejection in heart transplantation
G T Schnickel1, G R Hsieh, E L Kachikwu
1Department of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA. gschnickel@mednet.ucla.edu
Insights
Inducing heme oxygenase-1 (HO-1) with the peptide D4-F effectively reduced cardiac allograft vasculopathy (CAV) in a mouse model. This suggests anti-inflammatory peptides that induce HO-1 offer a new strategy for treating CAV.
Area of Science:
- Immunology
- Transplantation Biology
- Cardiovascular Research
Background:
- Chronic rejection, specifically cardiac allograft vasculopathy (CAV), is a primary cause of late mortality in heart transplant recipients.
- Current treatments for CAV are limited, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the efficacy of D4-F, an apolipoprotein A-I mimetic peptide, in attenuating CAV by inducing heme oxygenase-1 (HO-1).
Main Methods:
- A murine model of CAV was employed, involving heterotopic heart transplantation.
- Mice received daily treatments of saline (control), D4-F, D4-F plus a non-HO-1-affecting copper compound (CuPP), or D4-F plus a HO-1 inhibitor (SnPP).
- Donor hearts were analyzed on day 24 post-transplantation for intimal lesions.
Main Results:
- D4-F treatment significantly reduced intimal lesions in donor hearts, correlating with HO-1 upregulation.
- Co-administration with CuPP did not alter the protective effect of D4-F.
- Inhibition of HO-1 with SnPP partially reversed the protective effects of D4-F, indicating HO-1's crucial role.
Conclusions:
- Induction of HO-1 by the apoA-I mimetic peptide D4-F is an effective strategy for controlling CAV.
- Anti-inflammatory peptides that upregulate HO-1 represent a promising novel therapeutic approach for CAV treatment.
Abstract:
Chronic rejection in transplanted hearts or cardiac allograft vasculopathy (CAV) is the leading cause of late death among heart transplant recipients. We hypothesized that induction of HO-1 by D4-F, an apoA-I mimetic peptide with potent antiinflammatory/antioxidant properties, attenuated CAV. We utilized a previously characterized murine model of CAV. B6.C-H2(bml2) hearts were heterotopically transplanted into C57BL/6 mice. In the control group, recipient mice were treated with 20 microg of saline daily. In experimental group I, mice were treated daily with 20 microg of D4-F. In experimental group II, mice were treated daily with 20 microg of D4-F daily, plus CuPP, which does not have any effect on HO-1 activity. In experimental group III, recipient mice were treated with 20 mug of D4-F daily, plus SnPP, which is a competitive inhibitor of HO-1. Donor hearts were harvested on day 24 after transplantation. The donor hearts in the control group developed severe intimal lesions. In experimental group I, treatment with D4-F was associated with upregulation of HO-1 and a marked reduction in intimal lesions, which was consistent in experimental group II. In experimental group III, inhibition of HO-1 was associated with partial restoration of intimal lesions. Induction of HO-1 by an apoA-1 mimetic peptide was effective to control CAV. This class of antiinflammatory peptides, which show an ability to induce HO-1, provides a novel strategy for the treatment of CAV.
Related Concept Videos
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:28Kidney Transplant I: Introduction
01:40Cell-mediated Immune Responses